Search Results
Your search for The A,The A matches 32372 pages
Showing 27201 - 27250Effective Prevention Measures Urgently Needed to Prevent Global Cancer Crisis
Earlier this year the International Agency for Research on Cancer (IARC), an agency of the World Health Organization, launched a World Cancer Report 2014. The report, a collaboration of over 250 leading scientists from more than 40 countries, described multiple aspects of cancer research and...
Book Review: Breast Cancer, Break the Silence
This date has a special place in my heart, as well as the hearts of my children, my family and my loved ones. It was the day when my life—and my priorities—took a whole new direction.” So begins Breast Cancer, Break the Silence, a slim yet powerful and highly revealing booklet by Saudi Arabian...
Breaking the Silence About Breast Cancer in the Arab World
In 1974, First Lady Betty Ford spoke publicly about her breast cancer diagnosis and treatment. Remarkably, at the time of her action, public discussion of breast cancer in the United States was seen as off limits. Four decades later, cultural barriers to women’s health still exist, particularly in...
Radiation Oncologist Stephen Hahn, MD, to Join MD Anderson
Stephen Hahn, MD, has been named as the Division Head of Radiation Oncology and Chair of the Department of Radiation Oncology at The University of Texas MD Anderson Cancer Center. He joins MD Anderson on January 1, 2015. Dr. Hahn comes to MD Anderson from the University of Pennsylvania’s Perelman...
On Being A Mentee and the Value of the Conquer Cancer Foundation’s Career Development Award
At the ASCO Annual Meeting in June, the Conquer Cancer Foundation presented the 2014 recipients of prestigious grants and awards, including the Young Investigator Award, Career Development Award, and the Advanced Clinical Research Award in Breast Cancer. In announcing the awards, Charles W. Penley, ...
The Value of Lifelong Mentorship in Career Development
While the development of mentorship relationships is critical in launching and nurturing the academic careers of young investigators, it is also an essential component for continued success throughout their careers, according to Jennifer R. Brown, MD, PhD. Dr. Brown, Director of the CLL Center at...
IARC Calls on Countries With High Stomach Cancer Burden to Act to Prevent the Disease
A new report from the International Agency for Research on Cancer (IARC), an agency of the World Health Organization, urges health authorities of countries with high stomach cancer burden to include stomach cancer in their national cancer control programs and allocate more resources to control the...
Treating Sarcomas in 2014
In 2014, about 15,000 people in the United States will be diagnosed with some form of sarcoma, and of those, approximately 5,000 adults and children are expected to die of the disease. Sarcomas are a heterogeneous group of mesenchymal malignancies that have historically been difficult to diagnose...
Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 10, 2014, the androgen receptor inhibitor...
Improving Treatment of Depression in Patients With Cancer: The SMaRT Oncology-2 Trial
Clinical depression is highly prevalent, associated with significant morbidity, often underrecognized, and inadequately treated in cancer patients. Professor Michael Sharpe and Jane Walker, PhD, and their colleagues’ seminal work on enhancing treatment of depression in cancer patients using a...
Integrated Collaborative Care Program Highly Successful in Treating Major Depression in Patients With Cancer
In the Scottish SMaRT Oncology-2 study reported in The Lancet, Michael Sharpe, MD, and Jane Walker, PhD, of University of Oxford, United Kingdom, and colleagues found that an integrated collaborative treatment program for depression (“depression care for people with cancer”) was associated with...
Failure of Cilengitide in Newly Diagnosed Glioblastoma With Methylated MGMT Promoter
Temozolomide in combination with radiation for newly diagnosed glioblastoma was approved by the U.S. Food and Drug Administration in 2005—almost 10 years ago—but we have unfortunately made little progress in improving survival for this incurable brain tumor. Despite recent completion of three...
CENTRIC Trial Shows No Benefit of Adding Cilengitide to Therapy in Glioblastoma With Methylated MGMT Promoter
In the phase III CENTRIC/European Organisation for Research and Treatment of Cancer (EORTC) 26071-22072 trial reported in The Lancet Oncology, Roger Stupp, MD, of University Hospital Zurich, and colleagues found that adding the selective αvβ3 and αvβ5 integrin inhibitor cilengitide to standard...
Louis J. DeGennaro, PhD, Named President and Chief Executive Officer of The Leukemia & Lymphoma Society
The Leukemia & Lymphoma Society has announced that Louis J. DeGennaro, PhD, has been appointed as President and Chief Executive Officer, effective immediately. “Dr. DeGennaro has tirelessly dedicated himself for almost a decade of service to the Leukemia & Lymphoma Society mission and to...
ASCO Seeks Editor for New Global Oncology Journal
The American Society of Clinical Oncology (ASCO) is seeking candidates for the position of founding Editor-in-Chief for a new online-only, open-access journal focusing on cancer care, research, and care delivery issues unique to limited health-care resource countries and settings. The new journal...
ASCO President Peter P. Yu, MD, FASCO, Discusses CancerLinQ at Stanford Medicine X Conference
ASCO President Peter P. Yu, MD, FASCO, recently delivered a talk entitled “Learning from Every Patient” at the 2014 Stanford Medicine X Conference. Dr. Yu’s presentation focused on CancerLinQ and ASCO’s vision for using big data to drive progress in cancer care. To view Dr. Yu’s presentation, go to ...
ASCO, AACR Urge FDA to Regulate All Tobacco Products—Including E-Cigarettes
ASCO and the American Association for Cancer Research (AACR) sent a joint letter to the U.S. Food and Drug Administration (FDA) urging the agency to regulate electronic cigarettes, cigars, and all other tobacco products and to strengthen the proposed regulations for newly deemed products. The...
New Series Features Interviews With Authors of JCO and JOP Research
Journal of Clinical Oncology (JCO) and Journal of Oncology Practice (JOP) “Exclusive Coverage” summaries, available on ASCO.org and ASCO Connection, are designed to provide quick insight and additional author perspectives on select recently published studies. Based on interviews conducted with the...
For Your Patients: Video Series for Newly Diagnosed Patients on Navigating Common Challenges to Quality Care
The American Society of Clinical Oncology (ASCO) recently launched a new video series for people newly diagnosed with cancer through its patient education website, Cancer.Net. This initiative was made possible by a grant from the LIVESTRONG Foundation to the Conquer Cancer Foundation. After a...
Fellows’ Expectations of Work-Life Balance Not in Line With Realities of Practice
Oncology fellows just years away from entering the profession full time may have unrealistic expectations of their future career, according to data published recently in the Journal of Clinical Oncology. The study by Tait D. Shanafelt, MD, of the Mayo Clinic, Rochester, Minnesota, and colleagues...
Cancer Survivors Face Lasting Financial Struggles Long After Treatment Ends, New Study Reports
The majority (62%) of America’s middle-income cancer survivors say they were not financially prepared for cancer diagnosis and treatment, according to a new study released by the Washington National Institute for Wellness Solutions (IWS). The study, “Insights from Survivors: Managing the Personal,...
ECOG E4402/RESORT Trial: When ‘Black and White’ Results Are Actually Gray
The results of the ECOG E4402/RESORT trial recently reported by Kahl and colleagues,1 and reviewed in this issue of The ASCO Post, provide interesting new information on the use of maintenance rituximab (Rituxan) vs retreatment with rituximab at progression in patients with low–tumor burden...
Time to Treatment Failure Similar With Rituximab Retreatment vs Maintenance in Low–Tumor Burden Follicular Lymphoma
Maintenance rituximab (Rituxan) has been shown to improve progression-free survival vs observation in low–tumor burden follicular lymphoma. In the Eastern Cooperative Oncology Group (ECOG) E4402 Trial (RESORT), reported in the Journal of Clinical Oncology, Brad S. Kahl, MD, of the University of...
Early Study Reports Modified Vitamin D Has Potential in Treatment for Pancreatic Cancer
Researchers at the Salk Institute have reported on a synthetic derivative of vitamin D able to collapse the barrier of cells shielding pancreatic tumors, making this challenging cancer more susceptible to therapeutic drugs. The discovery has led to human trials for pancreatic cancer, even in...
Colonoscopic Polypectomy and Predicting Cancer Risk: A Work in Progress
Colon cancer screening using colonoscopy has significantly decreased the incidence and mortality of colorectal cancer in the United States. In the National Polyp Study (NPS), colorectal cancer was prevented by removal of adenomatous polyps.1 A more recent study looking at long-term follow-up from...
Lower- vs Higher-Than-Expected Long-Term Colorectal Cancer Mortality After Removal of Lower- vs Higher-Risk Adenomas
Few data are available on long-term risk of colorectal cancer mortality after adenoma removal. In a Norwegian study reported in The New England Journal of Medicine, Magnus Løberg, MD, of the Department of Health Management and Health Economics, University of Oslo, and colleagues found that patients ...
Advanced Robotic Technology Used to Remove Kidney Tumor in First-Time Outpatient Procedure
Keck Medical Center of the University of Southern California (USC) has become the first medical center in the world to use a new robotic technology in an outpatient procedure for a patient with kidney cancer. Urologic surgeons at the USC Institute of Urology, part of Keck Medicine of USC, used a...
First Approval of PD-1 Inhibitor: Pembrolizumab in Unresectable or Metastatic Melanoma
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On September 4, 2014, pembrolizumab (Keytruda) was granted...
Exceptional Responders to Cancer Therapy Study Begins
The National Cancer Institute (NCI) recently launched “The Exceptional Responders Initiative,” a study to investigate the molecular factors of tumors associated with exceptional treatment responses of patients with cancer to drug therapies. Scientists will attempt to identify the molecular features ...
Despite Growing Awareness, the Global Crisis of Untreated Cancer Pain Persists
Each day, millions of patients with cancer around the world suffer unrelieved pain because they are denied morphine, the gold standard of cancer pain control. The World Health Organization has called access to morphine a human rights issue. Not surprisingly, the crisis in unrelieved cancer pain is...
Life-Threatening Dermatologic Toxicity
A variety of life-threatening dermatologic adverse events may occur in association with cancer drug therapies. Here, we discuss the recognition and management of three types of such toxicities: type I hypersensitivity/anaphylaxis, Stevens-Johnson syndrome/toxic epidermal necrolysis, and drug rash...
Ohio State Opens First Fully Integrated Cancer Emergency Department
For patients with cancer who already have compromised immune systems, what may seem like a minor medical issue—ie, fever, dehydration, viral infection—can rapidly escalate into an emergency situation requiring care from a medical team familiar with managing the side effects of cancer treatment....
Women at Higher Risk for Breast Cancer to Benefit From Hereditary Risk Assessment Program in Tucson Center
Approximately 12% of women in the United States will develop breast cancer, according to the American Cancer Society. That’s more than 30,000 in Tucson alone, 2,500 of whom are estimated to have a genetic risk factor for cancer. In response to this growing concern, The Breast Center at Carondelet...
Statement from ASH President Linda J. Burns, MD, on Release of Sunshine Act Data
The Centers for Medicare & Medicaid Services (CMS) has released a large set of data about the payments physicians and teaching hospitals received from pharmaceutical and medical device companies from August 1 to December 31, 2013. This public disclosure, mandated under a provision of the...
NCI’s Center for Global Health Announces First Major Research Grants to Support Portable Technologies
The National Cancer Institute (NCI) Center for Global Health announced grants that will support the development and validation of low-cost, portable technologies. These technologies have the potential to improve early detection, diagnosis, and noninvasive or minimally invasive treatment of several...
Attaining the Goal of Preventing Ovarian Cancer
Fifteen years ago, David Fishman, MD, launched the National Ovarian Cancer Early Detection Program as part of the National Cancer Institute’s Early Detection Research Network. The goal of the research effort was to develop methods to accurately detect ovarian cancer while it was still confined to...
Call for Ideas for Ovarian Cancer Translational Research ‘Dream Team’ Grant
The American Association for Cancer Research (AACR) is accepting submissions of ideas for the Stand Up To Cancer–Ovarian Cancer Research Fund–Ovarian Cancer National Alliance–National Ovarian Cancer Coalition (SU2C-OCRF-OCNA-NOCC) Translational Research Dream Team Grant that will offer up to $6...
Guidelines and Care: What Comes Next?
The goal of clinical, translational, and basic research is, in the end, the betterment of life on earth. Advances in basic and clinical science ultimately should lead to information that, in turn, enables clinicians to make better treatment decisions for individual patients in order to improve...
ASCO Clinical Practice Guideline: Chemotherapy and Targeted Therapy in Advanced HER2-Negative or HER2 Status–Unknown Breast Cancer
The American Society of Clinical Oncology has released a new clinical practice guideline on chemotherapy and targeted therapy for women with advanced HER2-negative or HER2 status–unknown breast cancer. The guideline is published in the Journal of Clinical Oncology.1 In formulating the consensus...
Society Announces Candidates for 2015 ASCO Election
Fourteen distinguished ASCO members have been selected by the ASCO Nominating Committee as candidates for open leadership positions within the Society for the 2015 ASCO Election. Biographical information and interviews with each candidate, as well as instructions for casting a proxy ballot, will be ...
REVEL: Winning a Questionable Race
The investigators and sponsors of the phase III REVEL trial should be congratulated and probably commiserated. In this large study, reported by Garon and colleagues in The Lancet and reviewed in this issue of The ASCO Post, 1,253 patients with advanced non–small cell lung cancer (NSCLC) were...
Significant Improvement in Overall Survival With Second-Line Addition of Ramucirumab to Docetaxel in Stage IV NSCLC
In the phase III REVEL trial reported in Lancet, Edward B. Garon, MD, of the David Geffen School of Medicine at UCLA/Translational Research in Oncology–US Network, Los Angeles, and colleagues found that the addition of the antiangiogenic vascular endothelial growth factor receptor (VEGFR)-2...
Early Study Finds BRCA-Mutated Pancreatic Cancer Responds to PARP Inhibition Trio
Two-thirds of patients with advanced pancreatic adenocarcinoma who harbored BRCA mutations responded to the combination of veliparib, cisplatin, and gemcitabine in a phase IB trial that is paving the way for future studies of novel poly(ADP-ribose) polymerases (PARP) inhibitors in this challenging...
CancerCare® Awarded $1.5 Million Grant From Susan G. Komen®
CancerCare, a leading national nonprofit organization providing free, professional support services to anyone affected by cancer, has received a $1.5 million grant to assist people diagnosed with breast cancer. The grant will support a CancerCare program in partnership with Susan G. Komen called...
Aldoxorubicin Receives FDA Orphan Drug Designations for Glioblastoma, Small Cell Lung Cancer, and Ovarian Cancer
The U.S. Food and Drug Administration has granted Orphan Drug Designations to aldoxorubicin in three indications: glioblastoma multiforme, small cell lung cancer, and ovarian cancer. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to...
FDA Grants Orphan Drug Designation to Bivalent Vaccine for Neuroblastoma
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to MabVax Therapeutics’ vaccine for the treatment of relapsed or recurrent high-risk neuroblastoma in remission or with limited residual disease after best available treatment. The bivalent vaccine is intended to elicit ...
Aron Goldhirsch, MD, Receives 2014 Gianni Bonadonna Breast Cancer Award
Aron Goldhirsch, MD, was presented with the 2014 Gianni Bonadonna Breast Cancer Award and Lecture during the 2014 Breast Cancer Symposium, held recently in San Francisco. Dr. Goldhirsch is Director of the Multidisciplinary Program of Senology and Deputy Scientific Director at the European Institute ...
Expert Point of View: William M. Sikov, MD
At the Breast Cancer Symposium, William M. Sikov, MD, Associate Professor of Medicine at the Warren Alpert Medical School of Brown University, Providence, Rhode Island, gave a talk on the use of pathologic complete response in the clinic and summarized the CTNeoBC findings for The ASCO Post. “The...
CTNeoBC Analysis: Response to Neoadjuvant Chemotherapy Varies by Breast Tumor Subtype
Women who achieve a pathologic complete response (pCR) to neoadjuvant chemotherapy rarely have local or regional recurrence of breast cancer, but this largely depends on tumor subtype, which remained an independent predictor of locoregional recurrence when pathologic response was taken into account ...
Fertility Preservation Suggested With Triptorelin in Long-Term Study
Young women with early breast cancer may be more likely to resume menses and become pregnant when treated with a luteinizing hormone–releasing hormone (LH-RH) analog (also known as a gonadotropin-releasing hormone [GnRH] analog) along with chemotherapy, according to the final follow-up of...
